Gaudium IVF and Women Health Files DRHP With SEBI for An IPO

Gaudium IVF and Women Health, a New Delhi-based in vitro fertilisation (IVF) treatment provider, has filed draft papers with SEBI for an initial public offering (IPO). The funds raised will be utilised to support the company’s expansion plans, working capital needs, and the launch of FMCG products.

IPO Details and Financial Performance

Established in 2015 by Dr Manika Khanna, Gaudium IVF operates through over 30 locations across India, including 7 hubs and 28 spokes. The IPO comprises a fresh issuance of 1.83 crore equity shares and an offer-for-sale of 25.31 lakh shares by the promoter. Sarthi Capital Advisors is the sole book-running lead manager for the issue.

On the financial front, Gaudium IVF recorded a profit of ₹16.6 crore in FY24, marking a 22.7% growth from the previous year. Revenue for the same period increased by 20.9%, reaching ₹53.5 crore. For the six months ended September 2024, the company reported a profit of ₹8.1 crore on revenue of ₹31.7 crore.

Expanding the IVF Landscape in India

The proceeds from the fresh issue will fund the establishment of new IVF centres, meet working capital requirements, and support the launch of FMCG products. Gaudium IVF has positioned itself as a key player in the IVF sector, with no direct comparable peers among listed entities.

Meanwhile, Indira IVF, backed by EQT AB, is also planning an IPO to raise $400 million in 2025, potentially valuing the clinic operator at $2.5 billion.

Conclusion

Gaudium IVF’s IPO reflects its growth trajectory and commitment to expanding its footprint in India’s healthcare sector. The offering marks a significant step towards enhancing accessibility to IVF treatments across the country.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.